| Deal value | $58M |
|---|---|
| Share of market cap | 9.8% |
| Share of annual revenue | 129.1% |
Key highlights
- $10 million upfront license fee paid to Aquestive Therapeutics upon agreement execution
- Eligibility for up to $47.5 million in aggregate regulatory and commercial milestone payments
- Mid-teens percentage royalties on annual net sales of LIBERVANT in the United States
- 20-year exclusive supply agreement designating Aquestive as the sole manufacturer
- Anticipated commercial launch in April 2027 following expected FDA regulatory actions
What Is the Licensing Deal?
Aquestive Therapeutics has transitioned the commercial responsibilities for LIBERVANT, its proprietary diazepam buccal film, to Eton Pharmaceuticals under a new long-term licensing arrangement. This agreement covers the United States and its territories, granting Eton exclusive rights to market the treatment for acute seizure clusters in epilepsy patients. LIBERVANT utilizes Aquestive's PharmFilm technology, offering a portable and less invasive alternative to traditional rectal and nasal rescue therapies. As part of the transaction, Aquestive will maintain control over the production cycle, acting as the exclusive manufacturer and supplier for an initial 20-year term, ensuring ongoing operational involvement and steady industrial revenue.
Licensing Terms
- Initial payment of $10 million received upon the execution of the license agreement
- Commercial sale milestone of $10 million, contingent on FDA approval for pediatric patients aged 2 to 5
- Regulatory milestone of $2.5 million following FDA approval for patients aged 6 to 11
- Performance-based milestones totaling $35 million tied to specific annual net sales thresholds
- Recurring mid-teens percentage royalties on all net sales generated within the licensed territory
Management Perspective
“Today marks an important new chapter for LIBERVANT and for the epilepsy community. I am confident that Eton’s focus on specialty medicines and patient access will be essential as we work toward making LIBERVANT available to the epilepsy community.”
Financial Context
This licensing deal arrives as Aquestive Therapeutics reaffirms its 2026 financial outlook, projecting total revenues between $46 million and $50 million. The company is currently managing a non-GAAP adjusted EBITDA loss estimated at $30 million to $35 million for the fiscal year, highlighting the importance of non-dilutive capital such as the $10 million upfront fee from Eton. Beyond the LIBERVANT agreement, Aquestive previously secured a $75 million strategic funding package from RTW Investments to support its flagship Anaphylm program. The company's current market capitalization stands at approximately $586.1 million, with technical indicators reflecting a stable market position ahead of the scheduled 2027 product launch.
| Date | Announcement | Amount |
|---|---|---|
| 03 Mar 2026 | Amendment No. 1 to the Anaphylm strategic funding agreement and warrant issuance agreement with RTW InvestmentsSource: fundz.net | – |
| 14 Aug 2025 | Strategic funding and tiered royalty purchase agreement with RTW Investments to support Anaphylm launchSource: investors.aquestive.com | $75.0 Million |
Management commentary
“Today marks an important new chapter for LIBERVANT and for the epilepsy community. I am confident that Eton’s focus on specialty medicines and patient access will be essential as we work toward making LIBERVANT available to the epilepsy community.”
| Share price | $4.67 |
|---|---|
| Market cap | $586M |
| Revenue (annual) | $45M |
| 1-month price change | -2.30% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Aquestive Therapeutics, Inc. announcing a material definitive licensing and supply agreement with Eton Pharmaceuticals.
Track Aquestive Therapeutics, Inc. live
Get the next Aquestive Therapeutics, Inc. SEC filing seconds after it lands.
